Evidence map›Paper›PMID 35927231›Full record

ArticleSignal transduction and targeted therapy2022

Human umbilical cord mesenchymal stem cells for psoriasis: a phase 1/2a, single-arm study.

Lamei Cheng, Siqi Wang, Cong Peng, Xiao Zou, Chao Yang, Hua Mei, Chuang Li, Xian Su, Na Xiao, Qi Ouyang and 11 more

Open access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 2 countries.

Lamei Cheng *Institute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, 410031, China.ORCID 0000-0002-8685-3674
Siqi Wang *National Engineering Research Center of Human Stem Cell, Changsha, 410205, China.
Cong Peng *The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 410008, China.ORCID 0000-0001-7104-5490
Xiao ZouNational Engineering Research Center of Human Stem Cell, Changsha, 410205, China.
Chao YangNational Engineering Research Center of Human Stem Cell, Changsha, 410205, China.
Hua MeiNational Engineering Research Center of Human Stem Cell, Changsha, 410205, China.
Chuang LiNational Engineering Research Center of Human Stem Cell, Changsha, 410205, China.
Xian SuNational Engineering Research Center of Human Stem Cell, Changsha, 410205, China.
Na XiaoInstitute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, 410031, China.
Qi OuyangInstitute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, 410031, China.
Mi ZhangThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Qiaolin WangThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Yan LuoThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Minxue ShenThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Qun QinThe Office of Drug Clinical Trials Institution, Xiangya Hospital, Central South University, Changsha, 410031, China.
Honglin WangPrecision Research Center for Refractory Diseases,Shanghai General Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese, Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Wu ZhuThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 410008, China.ORCID 0000-0002-3645-7059
Guangxiu LuInstitute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, 410031, China.
Ge LinInstitute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, 410031, China. linggf@hotmail.com.
Yehong KuangThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 410008, China. yh_927@126.com.ORCID 0000-0002-1133-1791
Xiang ChenThe Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 410008, China. chenxiangck@126.com.ORCID 0000-0001-8187-636X
Central South University · CNNational Engineering Research Center of Human Stem Cells · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis is a common, chronic immune-mediated systemic disease that had no effective and durable treatment. Mesenchymal stem cells (MSCs) have immunomodulatory properties. Therefore, we performed a phase 1/2a, single-arm clinical trial to evaluate the safety and efficacy of human umbilical cord-derived MSCs (UMSCs) in the treatment of psoriasis and to preliminarily explore the possible mechanisms. Seventeen patients with psoriasis were enrolled and received UMSC infusions. Adverse events, laboratory parameters, PASI, and PGA were analyzed. We did not observe obvious side effects during the treatment and 6-month follow-up. A total of 47.1% (8/17) of the psoriasis patients had at least 40% improvement in the PASI score, and 17.6% (3/17) had no sign of disease or minimal disease based on the PGA score. And the efficiency was 25% (2/8) for males and 66.7% (6/9) for females. After UMSC transplantation (UMSCT), the frequencies of Tregs and CD4

Indexed as

Mesenchymal Stem CellsPsoriasisFemaleHumansMaleTreatment OutcomeUmbilical Cord

Identifiers

PMID35927231
PMCPMC9352692
OpenAlexW4289856259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.